• News Releases
  • Jun. 23, 2021 (PDF/221KB)Products
    Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
  • Jun. 09, 2021 (PDF/163KB)Licensing
    Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"
  • Jun. 03, 2021 (PDF/74KB)Corporate
    Comments Regarding Media Article on Our Company
  • May 27, 2021 (PDF/172KB)Products
    Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
  • May 24, 2021 (PDF/40KB)R&D
    Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

Other Notices